Work Here?
Overview
Aegis Ventures is a startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale new companies focused on AI and health tech. It operates a platform that combines market-shaping ideas, permanent growth capital, and ambitious people to identify opportunities, fund them long-term, and provide hands-on operational support. Unlike traditional funds, it creates companies in-house with a built-in path to rapid growth, with a strong emphasis on transforming healthcare quality, access, and cost. Its goal is to build companies capable of vast impact by using technology to improve health outcomes and societal wellbeing.
About Aegis Ventures
Industries
Venture Capital
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
$33.1M
Headquarters
New York City, New York
Founded
2020
Get referred to Aegis Ventures
See people who can refer or advise you
Simplify's Take
What believers are saying
- April 2026 Wavelet $7M seed expands Aegis into fetal medicine commercialization.
- May 2026 whitepaper and Bunny Ellerin hire signal aggressive platform-building in medtech AI.
- Portfolio now includes Ascertain, Avandra, Caregentic, Hume, Optain, and Wavelet, broadening optionality.
What critics are saying
- Ascertain launched in 2022; five companies still concentrate value in unproven early-stage bets.
- Wavelet needs regulatory clearance and hospital adoption before revenue, delaying scale.
- If Northwell or Yale withdraws, Aegis loses its core sourcing and distribution moat.
What makes Aegis Ventures unique
- Northwell partnership plus permanent growth capital gives proprietary clinical distribution.
- Yale relationship and 2026 Wavelet seed show university-to-market commercialization engine.
- Five launched AI health companies and $200M+ portfolio capital prove repeatable studio model.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$33.1M
Above
Industry Average
Funded Over
0 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Company Equity
Wellness Program
Mental Health Support
Company News
Wavelet Medical has secured $7 million in seed funding from Aegis Ventures to commercialise the first non-invasive, AI-powered fetal electroencephalography monitoring platform. The technology, developed at Yale, aims to detect fetal brain distress in real time and prevent avoidable brain injury at birth. Founded by Liz Golden, Dr Emily Lee and Dr Jose Cortes-Briones, Wavelet uses EEG captured through the mother's abdomen and reconstructed with AI algorithms to identify neurological distress, addressing limitations of traditional fetal heart rate monitoring, which is indeterminate in up to 85% of births. The platform targets a significant problem: over 35,000 infants suffer birth-related brain injuries annually in the US alone. Wavelet's partnership with Aegis Ventures will accelerate product development, clinical adoption and commercialisation of the technology.
/PRNewswire/ -- A breakthrough in fetal brain monitoring developed at Yale is moving from laboratory discovery to global commercialization through a pivotal...
From Knoxville: The Knoxville Technology Council is asking local business representatives to complete its latest KTech Pulse 2024 Survey. Noting that the organization wants to get the pulse of Knoxville-area... The post News Notes | FoundersForge joins Village Capitals Resource III Program for Entrepreneur Support Organizations appeared first on Teknovation.biz.
We are driven by the mission to build companies that solve society's greatest problems, informed by the belief that the nexus of profits and purpose will create a virtuous cycle of impact that moves the world forward.
Michalski, an Amazon alum, and Fergus, ex-CEO of 4Catalyzer, will lead the company creation platform building AI applications in healthcare.NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Ascertain, a healthcare AI company creation platform, today announced the formation of its leadership team with the appointment of CEO Mark Michalski, M.D. and Executive Chairman, Gregg Fergus. Michalski and Fergus will lead Ascertain in its mission to merge deep technical, operational, and clinical expertise to deliver high-quality, equitable, and affordable healthcare.Michalski brings two decades of executive leadership experience to Ascertain. Prior to Ascertain, Michalski led strategic development for healthcare and life sciences at Amazon, was Founding Executive Director at Mass General Brigham/Harvard's Center for Clinical Data Science, and served as President and CMO of two publicly traded companies - Butterfly Network and Hyperfine Research. He is a board-certified radiologist and completed his medical training at Yale and Stanford.Fergus and Michalski met and collaborated closely at the venture studio 4Catalyzer where Fergus was CEO, launching several leading healthcare companies including Butterfly Network, Hyperfine Research, AI Therapeutics, and Quantum Si
Aegis Ventures is Hiring for 11 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Aegis Ventures
Industries
Venture Capital
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
$33.1M
Headquarters
New York City, New York
Founded
2020
Aegis Ventures is Hiring for 11 Jobs on Simplify!
Find jobs on Simplify and start your career today